Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your voice may reveal if You're taking your psychiatric medication

NCT ID NCT06613334

NEW Knowledge-focused Sponsor: Centre Hospitalier St Anne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are studying whether voice recordings can show if people with schizophrenia are taking their antipsychotic medication. About 200 participants will use a smartphone app to record speech interviews and give blood samples over six months. The goal is to see if speech patterns match drug levels in the blood, which could lead to a simple tool for monitoring treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
voice analysis via a smartphone app compared with blood tests for antipsychotic levels
What this could lead to
If voice analysis works, doctors could use a simple app to check whether patients are taking their antipsychotic medication, helping prevent relapses without frequent blood draws.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove that voice monitoring improves outcomes. Speech patterns may not reliably reflect drug levels, and the approach needs validation in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Affiliated to a social security or other social protection scheme * Diagnosed with schizophrenia according to the DSM-5 (code F20) * Stable state without duration criteria * Main treatment with risperidone or paliperidone, aripiprazole, olanzapine in oral or long-acting injectable form * Complementary treatment with an antipsychotic for anxiolytic or sedative purposes: chlorpromazine, loxapine or cyamemazine * Able to speak and read French * Able to perform speech evaluations * Able to answer questionnaires on smartphone * May be under curatorship or guardianship * Agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under curatorship or guardianship Exclusion Criteria: * Suffering from a pathology that impairs French * Suffering from a neurological pathology: multiple sclerosis, Parkinson's disease, Huntington's disease or neurodegenerative disease * Treatment with lithium salts * Anti-epileptic treatment * Participant in another study involving medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences

    NOT_YET_RECRUITING

    Paris, 75014, France

  • Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, Paris

    RECRUITING

    Paris, Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.